| 臺大學術典藏 |
2020-04-28T07:25:13Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-28T07:25:13Z |
Right or left? Side selection for a totally implantable vascular access device: A randomised observational study
|
Shao Y.-Y.; Hsu M.-C.; Lin W.-Y.;Lin C.-P.;Chih-Hung Hsu;Lee Y.-H.;Lin Y.-T.;Hsu M.-C.;Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; CHIH-HUNG HSU; Lee Y.-H.; Lin Y.-T. |
| 臺大學術典藏 |
2020-04-28T07:25:11Z |
Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
|
Liu T.-H.; CHIH-HUNG HSU; Shao Y.-Y.; Liu T.-H.;Chih-Hung Hsu;Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-28T07:25:08Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chih-Hung Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; CHIH-HUNG HSU; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:51:19Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:17Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.;Lin Z.-Z.;Chiun Hsu;Shen Y.-C.;Hsu C.-H.;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:16Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Chiun Hsu ;Shen Y.-C. ;Hsu C.-H. ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:14Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Lin Z.-Z.; Chiun Hsu; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Cheng A.-L.; Yeh K.-H.; Chiun Hsu; Cheng W.-F.; Lin Y.-L.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:05Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Shao Y.-Y.;Chiun Hsu;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Chiun Hsu; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Chiun Hsu; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-09T09:43:08Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Wei, C. H.; Liang, Y. H.; Hsu, W. H.; Shao, Y. Y.; Lin, Y. C.; Chou, P. C.; Cheng, A. L.; Yeh, K. H. |
| 臺大學術典藏 |
2020-04-09T09:42:28Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao, Y.-Y.; Shau, W.-Y.; Chan, S.-Y.; Lu, L.-C.; Hsu, C.-H.; Cheng, A.-L. |
| 臺大學術典藏 |
2020-04-09T09:40:50Z |
Influence of age on opioid prescription of patients with advanced lung cancer
|
Shao, Y. Y.; Lin, C. P.; Chen, H. M.; Lee, H. S. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-04-09T09:31:03Z |
Key opioid prescription concerns in cancer patients: A nationwide study
|
Shao, Y. Y.; Lin, C. P.; Hsu, C. H.; Fu, W. M.; Chen, H. M.; Lee, Y. H.; Lai, M. S. |
| 臺大學術典藏 |
2020-03-23T07:19:27Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H.; Chang K.-J.; Kuo W.-H.; Lee W.-C.; Hsu C.; CHIUN-SHENG HUANG; Liau J.-Y.; Lu Y.-S.; Shao Y.-Y.;Kuo K.-T.;Hu F.-C.;Lu Y.-S.;Chiun-Sheng Huang;Liau J.-Y.;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Shao Y.-Y.; Kuo K.-T.; Hu F.-C. |
| 臺大學術典藏 |
2020-03-07T06:42:17Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.;Kuan-Ting Kuo;Hu F.-C.;Lu Y.-S.;Huang C.-S.;Liau J.-Y.;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Shao Y.-Y.; KUAN-TING KUO; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; MIN-SHU HSIEH; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H. |
